Product Information

PROLENSA 0.07% EYE DROPS is a brand product labeled by Bausch & Lomb Incorporated, priced at $115.5346 per ML under NDC 24208060203. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Apr 5, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Bromfenac Sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

PROLENSA 0.07% EYE DROPS

Bromfenac Sodium
$115.5346per ML
High Outlier

Strength

.7 mg/mL

NDC

24208060203

Classification

Brand

Dosage Form

SOLUTION/ DROPS

Route

OPHTHALMIC

Effective Date

8/19/2026

Active Ingredients

BROMFENAC SODIUM

Approval Type

New Drug (NDA)

FDA Application

NDA203168

FDA Approved

4/5/2013

TE Code

AB

On Market Since

4/5/2013

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price Statistics

The NADAC for PROLENSA 0.07% EYE DROPS has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 108.6%. The table below summarizes its recorded NADAC range and movement.

Current price$115.5346 per ML
All-time high$115.9006 (May 14, 2025)
All-time low$55.3975 (Nov 28, 2013)
52-week high$115.6373
52-week low$115.4578
Median price$90.2621
Average price$89.6123
Largest weekly change+10.0% (Jan 14, 2015)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

-0.0%

1M

-0.0%

3M

+0.1%

6M

+0.0%

1Y

-0.1%

3Y

+7.3%

5Y

+20.8%

All

+108.6%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 89% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of PROLENSA 0.07% EYE DROPS?

The current National Average Drug Acquisition Cost (NADAC) for PROLENSA 0.07% EYE DROPS, manufactured by Bausch & Lomb Incorporated, is $115.5346 per ML (NDC 24208060203), effective Aug 19, 2026.

How has the price of PROLENSA 0.07% EYE DROPS changed over time?

Over the history we have for it, the NADAC for PROLENSA 0.07% EYE DROPS has risen 108.6%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for PROLENSA 0.07% EYE DROPS?

Since Nov 28, 2013, the NADAC for PROLENSA 0.07% EYE DROPS has ranged from a low of $55.3975 (Nov 28, 2013) to a high of $115.9006 (May 14, 2025), with a median of $90.2621 per ML.

Are there cheaper alternatives to PROLENSA 0.07% EYE DROPS?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BROMFENAC SODIUM 0.07% EYE DRP, is $12.6625 per ML — about 89% below PROLENSA 0.07% EYE DROPS.

Who manufactures PROLENSA 0.07% EYE DROPS?

PROLENSA 0.07% EYE DROPS (NDC 24208060203) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.